2021 Samhain: The first clinical trial of South Korea’s homegrown next-generation chimeric antigen receptor T (CAR-T) cell therapy, which is designed to circumvent immune checkpoint signals, has recently gotten under way.
D'fhógair Ard-Institiúid Eolaíochta agus Teicneolaíochta na Cóiré (KAIST) Dé Céadaoin go bhfuil triail chliniciúil Chéim 1b dá theiripe cealla CAR-T á reáchtáil faoi láthair ag Ionad Leighis Samsung i Seoul. Tá an triail á déanamh le 10 n-othar as an gCóiré a bhfuil liomfóma mór B-chealla idirleata athiompaithe agus teasfhulangacha acu. Aistríodh na cearta margaíochta don phíblíne ón ollscoil go dtí an chuideachta Curocell, a chomhbhunaigh an tOllamh Kim Chan-hyuk. Tá Curocell i gceannas ar chlár forbartha cliniciúil an réabhlóideach immunotherapy.
In addition, a Phase 2 triail chliniciúil involving seventy participants is going to take place the following year to assess how safe and effective the investigational medication is.
The acronym CAR T, which stands for gabhdóir antaigin simléir T, is frequently referred to as a miracle cure. This is due to the fact that studies conducted in other countries on terminal blood cancer patients demonstrated that the therapy had a therapeutic effect of more than 80 percent. T cells from a patient are taken from the patient’s blood, genetically enhanced to make them more effective, and then reintroduced to the patient so that they can continue to fight and destroy cancer cells inside the patient’s body.
The research team that was led by Professor Kim of the Department of Biomedical Engineering at the KAIST confirmed an improved anticancer efficacy of CAR-T cells in mice with leukaemia and lymphoma. This was achieved by simultaneously inhibiting programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and ITIM domain (TIGIT), both of which are known to disturb the function of T cells. According to Professor Lee Young-ho, a post-doctoral researcher at KAIST and the first author of the animal model study, this dual blockade of PD-1 and TIGIT is a novel strategy to overcome the immunosuppression of existing CAR-T cells. This strategy was discovered by Prof. Lee Young-ho.
B’fhéidir gur mhaith leat léamh: Teiripe CAR T-Cell sa Chóiré
Cuireadh torthaí an staidéir i láthair in alt a foilsíodh ar líne in eagrán mhí Dheireadh Fómhair de Teiripe Mhóilíneach.
